Results 71 to 80 of about 45,148 (210)

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2010
Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer. Our previous experimental chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the ...
Wolfgang Hagmann, Ralf Jesnowski, Johannes Matthias Löhr   +2 more
doaj   +1 more source

Control of Gemcitabine Activity With Blue and Red Light

Chemistry – A European Journal, EarlyView.
Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten, Konstantin L. Stock, Marius Hyprath, Hannah Weisser, Timo Weinrich, Dieter Steinhilber, Alexander Heckel   +6 more
wiley   +1 more source

Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids.

PLoS ONE
BackgroundPancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic advancements and rapid development of treatment resistance.
Jonathan Barajas, Zhi Yang, Edward Agyare, Xueyou Zhu, Saun-Joo Yoon, Bo Han   +5 more
doaj   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression

Cancer Medicine, 2019
Increasing evidence revealed that ten‐eleven translocation 1 (TET1) plays an important role in tumorigenesis and chemoresistance, but its functions in gemcitabine resistance in cholangiocarcinoma (CCA) remain unknown.
Chuanxu Wang, Hua Ye, Lei Zhang, Yayu Cheng, Shifeng Xu, Ping Zhang, Zijie Zhang, Jimin Bai, Fangkang Meng, Lin Zhong, Guangjun Shi, Hao Li   +11 more
doaj   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Journal of Cancer, 2011
A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer.
Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
doaj